Literature DB >> 20938320

Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report.

Andrew Kennedy1, Douglas Coldwell, Bruno Sangro, Harpreet Wasan, Riad Salem.   

Abstract

Liver-directed therapies for unresectable cancers in the liver are evolving with increased efficacy and decreasing toxicity. One of these approaches uses radioactive microspheres delivered to hepatic tumors via the hepatic artery system-radioembolization. Use of this therapy is rapidly increasing worldwide with over 20,000 patients treated thus far. Therefore, greater understanding of its potential and optimal positioning of this therapy in the multimodality management of cancers affecting the liver is needed. This task has been undertaken by a group of the most experienced clinicians in radioembolization from multiple disciplines involved in this therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 20938320     DOI: 10.1097/COC.0b013e3181ec60b8

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  11 in total

Review 1.  Radioembolization of hepatic tumors.

Authors:  Andrew Kennedy
Journal:  J Gastrointest Oncol       Date:  2014-06

Review 2.  Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer.

Authors:  Lourens Bester; Baerbel Meteling; David Boshell; Akshat Saxena; David L Morris
Journal:  Hepat Oncol       Date:  2014-03-20

3.  Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization.

Authors:  Kazim H Narsinh; Mark Van Buskirk; Andrew S Kennedy; Mohammed Suhail; Naif Alsaikhan; Carl K Hoh; Kenneth Thurston; Jeet Minocha; David S Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Charles W Nutting; Fred M Moeslein; Michael A Savin; Sabine Schirm; Samuel G Putnam; Navesh K Sharma; Eric A Wang; Steven C Rose
Journal:  Radiology       Date:  2016-07-19       Impact factor: 11.105

Review 4.  Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors.

Authors:  Andrew Kuei; Sammy Saab; Sung-Ki Cho; Stephen T Kee; Edward Wolfgang Lee
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

5.  Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor: A Case Report and Review of the Literature.

Authors:  Anoopa A Koshy; Ilyssa O Gordon; Thuong G Van Ha; Edwin L Kaplan; Louis H Philipson
Journal:  J Investig Med High Impact Case Rep       Date:  2013-01-01

Review 6.  68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.

Authors:  Rudolf A Werner; Christina Bluemel; Martin S Allen-Auerbach; Takahiro Higuchi; Ken Herrmann
Journal:  Ann Nucl Med       Date:  2014-08-20       Impact factor: 2.668

7.  Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis.

Authors:  Sungwon Kim; Do Young Kim; Chansik An; Kyunghwa Han; Jong Yun Won; Gyoung Min Kim; Myeong Jin Kim; Jin Young Choi
Journal:  Korean J Radiol       Date:  2019-03       Impact factor: 3.500

8.  Celiac artery stenting to facilitate hepatic yttrium-90 radioembolization therapy.

Authors:  Murthy R Chamarthy; Terence W Hughes; Mohit Gupta; Josephina A Vossen; Noel B Velasco; Kenneth M Zinn
Journal:  Case Rep Radiol       Date:  2012-12-06

9.  A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization.

Authors:  Zhihong Weng; Judith Ertle; Shaoping Zheng; Thomas Lauenstein; Stefan Mueller; Andreas Bockisch; Guido Gerken; Dongliang Yang; Joerg F Schlaak
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

10.  Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.

Authors:  Zhihong Weng; Judith Ertle; Shaoping Zheng; Thomas Lauenstein; Stefan Mueller; Andreas Bockisch; Guido Gerken; Dongliang Yang; Joerg F Schlaak
Journal:  Oncol Lett       Date:  2013-10-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.